Rocket Pharmaceuticals
RCKT
51 hedge funds and large institutions have $15M invested in Rocket Pharmaceuticals in 2017 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 11 increasing their positions, 24 reducing their positions, and 21 closing their positions.
417% more call options, than puts
Call options by funds: $1.06M | Put options by funds: $205K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2.29% less ownership
Funds ownership: 9.59% → 7.3% (-2.3%)
24% less funds holding
Funds holding: 67 → 51 (-16)
28% less capital invested
Capital invested by funds: $20.7M → $15M (-$5.74M)
54% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 24
71% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 21
Top Buyers
| 1 |
Goldman Sachs
New York
|
+$214K |
| 2 |
Millennium Management
New York
|
+$211K |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
+$208K |
| 4 |
ECM
Element Capital Management
New York
|
+$171K |
| 5 |
LP
LMR Partners
London,
United Kingdom
|
+$124K |
Top Sellers
| 1 |
SCM
Sio Capital Management
New York
|
-$1.45M |
| 2 |
BlackRock
New York
|
-$1.29M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$718K |
| 4 |
FO
FT Options
Chicago,
Illinois
|
-$611K |
| 5 |
State Street
Boston,
Massachusetts
|
-$471K |
RCKT Hedge Fund Activity: Q2 2017 in Review
51 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Rocket Pharmaceuticals (RCKT) for Q2 2017, worth a combined $15M — down 28% from $20.7M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of RCKT and 6 opened new positions — a net loss of 15 holders — while 24 trimmed existing stakes and 11 added.
The largest buyer was Goldman Sachs, adding an estimated $214K. The largest seller was Sio Capital Management, exiting entirely with an estimated $1.45M sold.
- 51 institutional investors held Rocket Pharmaceuticals (RCKT) as of Q2 2017, down from 67 in Q1 2017.
- Funds reported $15M of Rocket Pharmaceuticals stock for Q2 2017, down 28% quarter-over-quarter.
- 6 funds opened new Rocket Pharmaceuticals positions in Q2 2017 and 21 closed out, a net change of -15 holders.
- The largest Rocket Pharmaceuticals buyer in Q2 2017 was Goldman Sachs, an estimated $214K added.
- The largest Rocket Pharmaceuticals seller in Q2 2017 was Sio Capital Management, an estimated $1.45M sold.
Based on aggregated 13F filings for Q2 2017.